重庆誉颜制药

Yuyan Pharma is a clinical-stage biotechnology company based in China, specializing in the development of recombinant botulinum toxin products for aesthetic and therapeutic applications. The company utilizes a proprietary recombinant protein expression platform to produce highly purified botulinum toxins without the use of animal-derived components or traditional Clostridium botulinum fermentation. Its lead candidate, YY001, is a recombinant botulinum toxin type A currently in Phase 3 clinical trials for the treatment of glabellar lines, making it one of the most advanced recombinant toxins in development globally. Beyond aesthetics, Yuyan Pharma is expanding its pipeline into medical indications such as cervical dystonia and muscle spasticity. The company is backed by prominent investors including Hillhouse Capital and Boyu Capital.